Rostam Namdari

Burnaby, BC, Canada

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 9 publications

Azetukalner, a Novel KV7 Potassium Channel Opener, in Adults With Major Depressive Disorder: A Randomized Clinical Trial.

Azetukalner, a Novel KV7 Potassium Channel Opener, in Adults With Major Depressive Disorder: A Randomized Clinical Trial.

Journal: JAMA network open

Published: May 27, 2025

Potent, Gut-Restricted Inhibitors of Divalent Metal Transporter 1: Preclinical Efficacy against Iron Overload and Safety Evaluation.

Potent, Gut-Restricted Inhibitors of Divalent Metal Transporter 1: Preclinical Efficacy against Iron Overload and Safety Evaluation.

Journal: The Journal of pharmacology and experimental therapeutics

Published: September 01, 2022

Pharmacokinetics of XEN496, a Novel Pediatric Formulation of Ezogabine, Under Fed and Fasted Conditions: A Phase 1 Trial.

Pharmacokinetics of XEN496, a Novel Pediatric Formulation of Ezogabine, Under Fed and Fasted Conditions: A Phase 1 Trial.

Journal: Neurology and therapy

Published: February 13, 2022

NBI-921352, a first-in-class, NaV1.6 selective, sodium channel inhibitor that prevents seizures in Scn8a gain-of-function mice, and wild-type mice and rats.

NBI-921352, a first-in-class, NaV1.6 selective, sodium channel inhibitor that prevents seizures in Scn8a gain-of-function mice, and wild-type mice and rats.

Journal: eLife

Published: July 24, 2021

Species selection for nonclinical safety assessment of drug candidates: Examples of current industry practice.

Species selection for nonclinical safety assessment of drug candidates: Examples of current industry practice.

Journal: Regulatory toxicology and pharmacology : RTP

Published: April 28, 2021

Safety and Efficacy of a Topical Sodium Channel Inhibitor (TV-45070) in Patients With Postherpetic Neuralgia (PHN): A Randomized, Controlled, Proof-of-Concept, Crossover Study, With a Subgroup Analysis of the Nav1.7 R1150W Genotype.

Safety and Efficacy of a Topical Sodium Channel Inhibitor (TV-45070) in Patients With Postherpetic Neuralgia (PHN): A Randomized, Controlled, Proof-of-Concept, Crossover Study, With a Subgroup Analysis of the Nav1.7 R1150W Genotype.

Journal: The Clinical journal of pain

Published: March 08, 2017

Discovery of thiazolylpyridinone SCD1 inhibitors with preferential liver distribution and reduced mechanism-based adverse effects.

Discovery of thiazolylpyridinone SCD1 inhibitors with preferential liver distribution and reduced mechanism-based adverse effects.

Journal: Bioorganic & medicinal chemistry letters

Published: October 08, 2013

Letter to the editor.

Letter to the editor.

Journal: Pain

Published: September 11, 2013

Human Mendelian pain disorders: a key to discovery and validation of novel analgesics.

Human Mendelian pain disorders: a key to discovery and validation of novel analgesics.

Journal: Clinical genetics

Published: June 14, 2012

Showing 1-9 of 9

Last Updated: 09/26/2026